316 related articles for article (PubMed ID: 28692055)
21. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.
Ammoun S; Schmid MC; Zhou L; Ristic N; Ercolano E; Hilton DA; Perks CM; Hanemann CO
Oncogene; 2012 Mar; 31(13):1710-22. PubMed ID: 21892205
[TBL] [Abstract][Full Text] [Related]
22. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
24. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
25. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
26. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
28. Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.
Doddrell RD; Dun XP; Shivane A; Feltri ML; Wrabetz L; Wegner M; Sock E; Hanemann CO; Parkinson DB
Brain; 2013 Feb; 136(Pt 2):549-63. PubMed ID: 23413263
[TBL] [Abstract][Full Text] [Related]
29. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
30. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
31. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.
Poulikakos PI; Xiao GH; Gallagher R; Jablonski S; Jhanwar SC; Testa JR
Oncogene; 2006 Sep; 25(44):5960-8. PubMed ID: 16652148
[TBL] [Abstract][Full Text] [Related]
32. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
33. Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate.
Sun CX; Haipek C; Scoles DR; Pulst SM; Giovannini M; Komada M; Gutmann DH
Hum Mol Genet; 2002 Dec; 11(25):3167-78. PubMed ID: 12444101
[TBL] [Abstract][Full Text] [Related]
34. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
35. Role of Merlin/NF2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract][Full Text] [Related]
36. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
37. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
38. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.
Chen H; Xue L; Huang H; Wang H; Zhang X; Zhu W; Wang Z; Wang Z; Wu H
EBioMedicine; 2018 Oct; 36():252-265. PubMed ID: 30274821
[TBL] [Abstract][Full Text] [Related]
40. Genetics of familial and non-familial skull base tumours.
Irving RM; Moffat DA; Maher ER
Clin Otolaryngol Allied Sci; 1995 Feb; 20(1):5-11. PubMed ID: 7788935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
